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Abstract: There is strong evidence that altered immunological function entails an increased risk of B-cell chronic
lymphocytic leukemia (B-CLL). The main mechanism of an anti-tumor response depends on T-cell activation.
Unlike the constitutively expressed CD28, inducible costimulatory molecule (ICOS) is expressed on the T-cell
surface after activation. ICOS enhances all the basic T-cell responses to a foreign antigen, namely proliferation,
secretion of lymphokines, the upregulation of molecules that mediate cell-cell interaction, and effective help for
antibody secretion by B cells. ICOS is essential for both efficient interaction between T and B cells and normal
antibody responses to T cell-dependent antigens. It does not upregulate the production of interleukin-2, but
superinduces the synthesis of interleukin-10. Our previous results indicated the ICOS gene has a role as a suscep-
tibility locus to B-CLL. Therefore an extended study was undertaken to evaluate the association between four
ICOS polymorphisms (which were recently described as functional ones) and susceptibility to B-CLL in the
Polish population. A case-control study of 296 individuals, including 146 B-CLL patients, was conducted on four
polymorphisms in the ICOS gene. Genotyping of the polymorphisms ICOS ISV1+173T>C (rs10932029),
ICOSc.1624C>T (rs10932037), ICOSc.2373G>C (rs4675379), and ICOSc.602A>C (rs10183087) was carried
out using allelic discrimination methods with the TaqMan® SNP Genotyping Assay. There were no statistically
significant differences in the allele, genotype, or haplotype distributions between B-CLL patients and healthy
controls for any of the investigated polymorphic markers in the ICOS gene. However, we noted that patients
carrying genotype ICOS ISV1+173T>C [TT], ICOSc.602A>C [AA], ICOSc.1624C>T [CC], and ICOSc.2373G>C
[GG] have a decreased frequency of progression to a higher Rai stage during 60-month follow-up (21.35% vs.
40.8%, p = 0.013) compared to other individuals. This indicates that the investigated polymorphisms do not modu-
late the risk of B-CLL in the Polish population, but are associated with disease dynamics, in particular with the time
to Rai stage progression. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 49–54)
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Introduction
There is strong evidence that altered immunological
function entails an increased risk of lymphoma [1].
The main mechanism of an anti-tumor response de-
pends on T-cell activation [2]. Naive T cells need two
signals for full activation. The first antigen-specific
signal is provided by the interaction of T cells with
a peptide of the major histocompatibility complex
(MHC) on antigen-presenting cells (APCs), whereas
the second signal is delivered by a T-cell co-stimula-
tory molecule [3]. CD28 is the primary T-cell co-stimu-
latory molecule constitutively expressed on the ma-
jority of T cells. Upon interaction with its ligands CD80
and CD86, CD28 transduces a signal that enhances
the activation and proliferation of T cells [4, 5].
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Inducible co-stimulator (ICOS) plays a role in
T-cell activation which is critical, independent, and
synergic with CD28 signaling. ICOS augments the
effector T-cell cytokine response, in particular the pro-
duction of IL-4, IL-5, IL-10, IFN-alpha, and IFN-
-gamma [6], but not IL-2 [7]. ICOS is expressed at
low levels on resting naive T cells and is rapidly up-
regulated following TCR ligation and CD28 stimula-
tion [7, 8].
After activation, ICOS is expressed on unpolarized
CD4+ cells as well on Th1, Th2, Th17, and Treg sub-
populations [8–12]. This co-stimulatory molecule
binds the B-7-related protein B7RP-1 [13]. ICOS
knockout mice have reduced CD4+ T-cell responses
and increased risk of experimental autoimmune en-
cephalomyelitis [14], defects in immunoglobulin class
switching, and germinal center formation [15].
Homozygous loss of the ICOS gene is the cause
of the ICOS deficiency (ICOSD) form of common
variable immunodeficiency (CVID), which is chara-
cterized by recurrent bacterial infections of the res-
piratory and digestive tracts characteristic of humo-
ral immunodeficiency, but without other complica-
ting features such as splenomegaly, autoimmune phe-
nomena, or sarcoid-like granulomas and the absence
of clinical signs of overt T-cell immunodeficiency [16].
Severe disturbance of T cell-dependent B-cell matu-
ration occurs in secondary lymphoid tissue; B cells
exhibit a naive IgD+/IgM+ phenotype and the num-
bers of IgM memory and switched memory B cells
are substantially reduced in those individuals [16].
The ICOS gene, located on chromosome 2q33 in
a region adjacent to the CTLA-4 and CD28 genes,
contains five exons. Exons 1–4 are parallel to those
of CD28 and CTLA-4, where exon 1 encodes the lead-
er peptide, exon 2 the ligand binding domain, exon 3
the transmembrane segment, and exon 4 determines
the cytoplasmic tail, while exon 5 encodes an addi-
tional fragment of the cytoplasmic tail (Figure 1).
Several polymorphisms have been found in the ICOS
gene: two microsatellite in the fourth intron and 31
single-nucleotide polymorphisms (SNPs) (http://
//www.hapmap.org). None of the described ICOS SNPs
leads to changes in amino acid, while a few have been
demonstrated to be functional variants [17–20]. The
chromosomal region of 2q33 harboring the CD28,
CTLA-4, and ICOS gene family has been described
as carrying predisposing genes for several autoim-
mune diseases [19, 21–23] and, recently, for cancer
[24–26]. Our recent results indicate that the ICOS
microsatellite polymorphism c.1554+4GT(8_15) is
associated with susceptibility to B-CLL [24].
This current study investigated the association be-
tween ICOS ISV1+173T>C (rs10932029),  ICOSc.602-
A>C (rs10183087),  ICOSc.1624C>T (rs10932037),
and ICOSc.2373G>C (rs4675379), which have been
recently reported to be functional polymorphisms, with
susceptibility to B-CLL. The ICOSc.1624C>T polymor-
phism was shown to influence ICOS mRNA level [17]
and the ICOSc.602A>C, ICOSc.1624C>T, and
ICOSc.2373G>C SNPs influence functions of the ICOS
gene [19]. The ICOS ISV1+173T>C polymorphism,
located close to the CTLA-4 gene, has been reported
to affect the expression of CTLA-4 isoforms [17].
Material and methods
Study population
The study group comprised 146 B-CLL patients (66 fe-
males and 78 males) with a mean age of 66.23 ± 11.14
years. The mean age at diagnosis was 62.23 ± 10.64
Figure 1. Structure of genes on chromosomal region 2q33 harboring the CD28, CTLA-4 and ICOS genes and location
of studied polymorphisms (distances not to scale)
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years. Diagnosis of B-CLL was established on the
basis of standard clinical and laboratory criteria fol-
lowing the National Cancer Institute recommenda-
tions. B-CLL stage 0 was found in 43 patients, and
stages I, II, III, and IV were diagnosed in 50, 26, 10
and 17 cases, respectively, according to Rai staging [27].
Mean follow-up was 77.6 months (range: 12–180
months) and data was available for 123 B-CLL pa-
tients. During 60 months of follow-up, lymphocyte
counts doubled in 32 patients in the peripheral blood,
and in five patients later. In 38 patients, progression
to a higher Rai stage occurred.
Chlorambucil was given as the front-line therapy
to all patients requiring treatment and purine ana-
logue-based protocols were used in the treatment of
refractory/relapsed cases.
The control population comprised 150 healthy age-
-matched subjects (70 females, 80 males) originating
from the same geographical area as the patients.
Genotyping/determination of polymorphisms
Genomic DNA was isolated using the NucleoSpin®Blood
kit (Macherey-Nagel, Germany) from whole frozen blood.
Genotyping of polymorphisms was carried out using al-
lelic discrimination methods with the TaqMan® SNP
Genotyping Assay: ICOS ISV1+173T> C (rs10932029),
assay ID C___430013_10; ICOSc.1624C>T
(rs10932037), assay ID C__30981474_10; ICOSc.2373-
G>C (rs4675379), assay ID C__27968684_10; and
ICOSc.602A>C (rs10183087), assay ID- C__30421029_10
(Applied Biosystems, Foster City, CA, USA).
Statistical analyses
Evaluation of the Hardy–Weinberg equilibrium
(HWE) was performed for the whole studied group
by comparing the observed and expected frequencies
of genotypes using c2 analysis. The c2 test was used to
compare categorical date between patients with B-CLL
and controls. Differences were considered statistically
significant if the p value was < 0.05. Because of the
multiple comparisons of genotype and haplotype fre-
quencies, Bonferroni multiple adjustments were em-
ployed to the level of significance. Odds ratios (OR)
and 95% confidence intervals (95% CI) were calcu-
lated using (http://www.quantitativeskills. com/sisa/sta-
tistics/twoby2.htm) software [28]. Linkage disequilib-
rium (LD) coefficients D’ = D/Dmax and r
2 values for
the pair of the most common alleles at each locus and
haplotype frequency for pairs of alleles was estimated
using the SHEsis program (http://202.120.7.14/analy-
sis/myAnalysis.php) [28]. The cumulative probabili-
ties of survival without lymphocyte doubling (lympho-
cyte-doubling free survival) and of survival without
progression to a higher Rai stage (progression–free
survival) during 60-month follow-up were calculated
according to the Kaplan–Meier method. We used as
endpoints the doubling of peripheral lymphocyte count
and progression to a higher Rai stage. Kaplan–Meier
curves were compared using the log-rank test.
Results
The distributions of the alleles and genotypes of all
the studied polymorphisms in the B-CLL patients and
the healthy control group are shown in Table 1. Nei-
ther in the cases, nor in the controls, was deviation
from Hardy–Weinberg equilibrium observed (Table 1).
The distributions of the alleles and genotypes for all
the studied polymorphisms were similar in the patients
and controls (Table 1). No significant prevalence of
the ICOSc.2373G>C[G] allele in B-CLL patients
compared to controls (89.2 vs. 86.1%) was noted.
The global distributions of the haplotypes did not
differ in the cases and controls (p = 0.5). The frequen-
cy of haplotype ICOS ISV1+173T>C[T], ICOSc.1624-
C>T[C], ICOSc.602A>C[A], ICOSc.2373G>C[G] was
the highest and similar in both the studied groups
(74.0% vs. 71.2%). The haplotype ICOS ISV1+173-
T>C[C], ICOSc.1624C>T[C], ICOSc.602A>C[A],
ICOSc.2373G>C[G] was overrepresented in the B-
CLL patients, but the difference was not statistically
significant (5.9% vs. 3.6%, OR 1.6, p = 0.24).
The features of the ICOS gene polymorphisms
were subjected to analysis for correlation with clini-
cal data, i.e. gender, age at diagnosis, peripheral lym-
phocyte doubling time, and the time to Rai stage pro-
gression. No associations were observed between any
of the ICOS gene polymorphisms and gender, age at
diagnosis, survival, or peripheral lymphocyte doubling
time. Kaplan–Meier analysis showed that the ICOS
ISV1+173T>C and ICOSc.602A>C polymorphisms
influenced the time of Rai progression. During 60
months of follow-up, only 24.4% of the patients with
ICOS ISV1+173T>C [TT] progressed to a higher
Rai stage, compared to 44.5% of the patients carry-
ing [CT] (p = 0.0248) (Figure 2A). Additionally,
the ICOSc.602A>C polymorphism showed an as-
sociation with decreased frequency of progression
to a higher Rai stage. Progression of Rai stage du-
ring the 60 month follow-up occurred only in 21.5%
of the patients with ICOSc.602A>C [AA] and in
39.5% of the patients carrying the C allele [CA+CC
genotype] (p = 0.049) (Figure 2B).
Moreover, homozygosity in the most frequent
genotype (AA according to Castelli et al. [19]) ICOS
ISV1+173T>C[TT], ICOSc.1624C>T[CC],
ICOSc.602A>C[AA], ICOSc.2373G>C[GG] was
associated with a significantly decreased frequency
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of progression to a higher Rai stage during 60-month
follow-up (21.35% vs. 40.8%, p = 0.013) compared
to the other individuals (Figure 2C).
The observed linkage disequilibria between investi-
gated polymorphisms were expressed only by D’, but
not by r2, and were as follows: ICOS ISV1+173T>C
and ICOSc.1624C>T (D’= 0.929, r2 = 0.009),
ICOSc.1624C>T and ICOSc.602A >C (D’= 0.914,
r2 = 0.302),  ICOSc.1624C>T and ICOSc.2373G>C
(D’= 1, r2 = 0.013), ICOSc.602A>C and ICOSc.
2373G>C (D’= 0.883, r2 = 0.424).
Discussion
The development of B-CLL may be regarded as
a failure of immunological surveillance; therefore genes
involved in the regulation of the immunological re-
sponse might be considered as predisposing loci for
disease development. Our previous study indicated
that CTLA-4g.319C>T, CD28c.17+3T>C, and mi-
crosatellite ICOSc.1554+4GT(8_15) polymorphisms
are associated with susceptibility to B-CLL [24].
In the present study, we extended our investiga-
tion to subsequent ICOS gene polymorphisms which
were recently described as functional ones [17, 19]
and were shown to be associated with susceptibility
to multiple sclerosis [19] and outcome after renal [18]
or hematopoietic stem cell transplantation [29], but
not to melanoma [30].
Table 1. ICOS ISV1+173T>C, ICOSc.602A>C, ICOSc.1624C>T, ICOSc.2373G>C genotypes and alleles frequencies
in B-CLL patients and controls
B-CLL Controls group Global p O R 95% CI
n = 146 n = 150
ICOS ISV1+173T>C Genotype T T 112 (0.778) 119 (0.815) Reference
T C 32 (0.222) 26 (0.178) 0.46 1.25 0.70–2.21
C C 0 (0.0) 1 (0.007) – –
Allele T 256 (0.888) 264 (0.904)
0.64
0.88 0.52–1.52
C 32 (0.112) 28 (0.096) 1.13 0.66–1.92
 ICOSc.1624C>T Genotype CC 119 (0.826) 125 (0.850) Reference
CT 24 (0.167) 19 (0.129) 0.43 1.32 0.69–2.53
TT 1 (0.007) 3 (0.020) 0.35 0.04–3.40
Allele C 262 (0.910) 269 (0.915)
0.82
0.93 0.52–1.65
T 26 (0.090) 25 (0.085) 1.07 0.69–1.92
ICOSc.602A>C Genotype AA 90 (0.625) 93 (0.628) Reference
AC 50 (0.347) 48 (0.324 ) 0.65 1.08 0.66–1.76
CC 4 (0.028) 7 (0.047) 0.59 0.17–2.08
Allele A 230 (0.799) 234 (0.791)
0.81
1.05 0.70–1.57
C 58 (0.201) 62 (0.209) 0.95 0.64–1.43
ICOSc.2373G>C Genotype G G 114 (0.792) 112 (0.757) Reference
G C 29 (0.201) 31 (0.209 0.26 0.92 0.52–1.63
C C 1 (0.007) 5 (0.034) 0.20 0.03–1.70
Allele G 257 (0.892) 255 (0.861)
0.26
1.33 0.81–2.17
C 31 (0.108) 41 (0.139) 0.75 0.46–1.24
Kaartinen et al. [17] showed that activated CD4+
T cells from ICOSc.1624C>T [CC] homozygous per-
sons had higher actual levels of ICOS mRNA than
cells from [TC] heterozygous persons after 1 h and
3 h of activation, after which this difference disap-
peared. Castelli et al. [19], investigating variations
in the ICOS gene 3’UTR, showed the presence of
three major haplotypes associated with different ca-
pacities of expression of ICOS in CD3+ cells and
IL-10 secretion. The polymorphisms we chose iden-
tify the same haplotypes, since it was shown that
SNPs at positions +602, +1564 and +2007 are in
complete LD and the same is true for +930, +1495,
+1624, and +1862. The AA genotype characterized
by the presence of ICOSc.1624C>T [CC],
ICOSc.602A>C[AA], and ICOSc.2373G>C[GG]
was shown to be associated with the lowest percent-
age of CD3+ activated cells expressing ICOS and
the highest IL-10 secretion. Moreover, according to
an Italian study [19], the frequency of the AA geno-
type was significantly lower in MS patients with re-
lapsing-remitting disease than in controls, and those
patients had a lower relapse rate and MS severity
score.
The ICOSc.602A>C and ICOSc.1624C>T poly-
morphisms have been described as susceptibility
markers of outcome after renal transplantation [18]
and hematopoietic stem cell transplantation [29]. The
ICOSc.602A>C and ICOSc.1564T>C SNPs were
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shown to be associated with delayed graft function
and the ICOSc.1624C>T polymorphism with graft
survival after renal transplantation. Hematopoietic
stem cell transplantation recipients who received
a graft from a donor with ICOSc.602A>C [CC] gen-
otype had worse disease-free survival, and recipients
of homozygous ICOSc.1624C>T [TT] had worse
overall survival.
Additionally, we included the ICOS ISV1+173T>C
polymorphism in our study, which does not influence
ICOS mRNA level in CD4+ cells but, since this poly-
morphism is located near the CTLA-4 gene, variations
at that position influence CTLA-4 mRNA expression
for both CTLA-4 isoforms, the soluble and full length
(membrane) [17].
Our study found linkage disequilibria between the
polymorphisms ICOSc.602A>C, ICOSc.1624C>T,
and ICOSc.2373G>C similar to those described by
the Italian group [19]. Weak LD was found between
ICOS ISV1+173T>C and ICOSc.1624C>T, while
the ICOSc.602A>C and ICOSc.2373G>C genetic
markers are not in linkage disequilibrium with the
ICOS ISV1+173T>C polymorphism.
We could not find any statistical differences in the
frequencies of alleles, genotypes, or haplotypes of any
of the investigated polymorphisms between B-CLL
patients and controls. However, we noted that ICOS
ISV1+173T>C [TT] alone and ICOSc.602A>C [AA]
alone and together as part of the genotype AA accor-
ding to Castelli et al. [19]: ICOS ISV1+173T>C [TT],
ICOSc.602A>C [AA], ICOSc.1624C>T [CC], and
ICOSc.2373G>C [GG], were associated with a lower
rate of disease progression. Only about 20% of ho-
mozygous patients carrying the genotype ICOS
ISV1+173T>C [TT], ICOSc.602A>C [AA],
ICOSc.1624C>T [CC], and ICOSc.2373G>C [GG]
increased Rai stage during the 60 months of follow-
-up, but more than 40% of the patients possessing
other genotypes did.
We cannot yet provide an explanation for this find-
ing. As a matter of fact, the AA genotype of the ICOS
gene is supposed to impair the expression of ICOS
molecule [19] and thus impair the T cell-mediated
response and T-cell dependent maturation of B-cells.
This finding warrants further studies of the role of
ICOS gene polymorphism in B-CLL dynamics.
To sum up, although the functional genetic mar-
kers of the ICOS gene ICOSISV1+173T>C,
ICOSc.602A>C, ICOSc.1624C>T, and ICOSc.2373-
G>C we chose were not found to be associated with
B-CLL susceptibility in the Polish population, they
were associated with disease dynamics, in particular
with the time to Rai stage progression.
Figure 2. Influence of ICOS gene polymorphisms on Rai
stage progression. A Kaplan–Meier estimate of Rai stage
progression according to: A. ICOS ISV1+173T>C;
B. ICOSc.602A>C; C. and combined ICOS ISV1+173T>C,
ICOSc.602A>C, ICOSc.1624C>T, ICOSc.2373G>C
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